CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Cincinnati, Ohio, United States and 165 other locations
vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...
Phase 3
Cincinnati, Ohio, United States and 192 other locations
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...
Phase 3
Cincinnati, Ohio, United States and 286 other locations
monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...
Phase 2
Cincinnati, Ohio, United States and 140 other locations
III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...
Phase 3
Cincinnati, Ohio, United States and 260 other locations
To evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers. Pati...
Phase 1, Phase 2
Cincinnati, Ohio, United States of America and 11 other locations
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase...
Phase 1
Cincinnati, Ohio, United States and 39 other locations
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic c...
Phase 1
Cincinnati, Ohio, United States and 12 other locations
with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended d...
Phase 1
Cincinnati, Ohio, United States and 11 other locations
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 58 other locations
Clinical trials
Research sites
Resources
Legal